A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
RemeGen Co., Ltd.
Shanghai Chest Hospital
M.D. Anderson Cancer Center
AstraZeneca
University of Rochester
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Tesaro, Inc.
University Health Network, Toronto
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Inspirna, Inc.
UNC Lineberger Comprehensive Cancer Center
Boehringer Ingelheim
Blueprint Medicines Corporation
AstraZeneca
Arcus Biosciences, Inc.
The Netherlands Cancer Institute
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
Cantargia AB
Blueprint Medicines Corporation
Aileron Therapeutics, Inc.
Merck Sharp & Dohme LLC
Novartis
Tianjin Medical University Cancer Institute and Hospital
Augusta University
Augusta University
Eli Lilly and Company
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
BioNTech SE
Novartis
Barbara Ann Karmanos Cancer Institute
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Tianjin Medical University Cancer Institute and Hospital
Gilead Sciences
Incyte Corporation